Skip to content

The effect of vitamin D supplementation on blood pressure in hypertensive patients with vitamin D deficiency

The effect of vitamin D supplementation on blood pressure in hypertensive patients with vitamin D deficiency

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT2012090310724N1
Enrollment
48
Registered
2012-09-25
Start date
2012-09-23
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hypertension. Essential (primary) hypertension

Interventions

Intervention 1: 50000IU vitamin D3 pearl(oral supplements),for 8 weeks, one pearl per week. Intervention 2: placebo pearl, for 8 weeks, one pearl per week.
Treatment - Drugs
Placebo
50000IU vitamin D3 pearl(oral supplements),for 8 weeks, one pearl per week
placebo pearl, for 8 weeks, one pearl per week

Sponsors

Vice chancellor for research, Shahid Sadoogi University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
25 Years to 50 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: patients with Systolic Blood Pressure equal or more than 140 mmHg ; and Diastolic Blood Pressure equal or more than 90 mmHg. ; and serum 25-hydroxy vitamin D3 lower than 30 ng/ml ; living in Yazd province; aged 25-50 years; not to be alcohol user or smoker or addicted ; without any liver or Coronary-artery or renal or Gastro Intestinal disorders; not using oral or injection of corticosteroids; not using cardiac glycosides or antiepileptic drugs; not using multi vitamins or supplements containing vitamin D, Calcium, Magnesium, Phosphorus or their analogs in past 3 mounts; not using injection of vitamin D in past 6 mounts; Exclusion criteria: any change in dosage or type of anti hypertension drugs; not following the study protocol. Exclusion criteria: any change in dosage or type of anti hypertension drugs; not following the study protocol.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Hypertension. Timepoint: before and 8 week after intervention. Method of measurement: mercurial sphygmomanometer.

Secondary

MeasureTime frame
Serum Calcium. Timepoint: before and 8 weeks after intervention. Method of measurement: laboratory biochemical measurements.;Serum 25- Hydroxy vitamin D. Timepoint: before and 8 weeks after intervention. Method of measurement: laboratory biochemical measurements _nmol/lit.;Serum PTH. Timepoint: before and 8 weeks after intervention. Method of measurement: laboratory biochemical measurements.;Serum phosphorus. Timepoint: before and 8 weeks after intervention. Method of measurement: laboratory biochemical measurements.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Mohammadreza Mirjalili

Shahid sadoogi University Of Medical Sciences and Health Services

drmirjalili@yahoo.com+98 35 1724 0172

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026